GlobeNewswire·Oct 23, 2026, 9:15 AM ET

Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress

Eikon Therapeutics presented updated data for EIK1003, initial data for EIK1004, & preliminary data for EIK1005 at the 2026 ESMO Congress in Madrid.
EIK1003, a non-brain-penetrant PARP1 inhibitor, showed a generally well-tolerated safety profile in monotherapy with 65 participants across multiple cancer types.
In Cohort 1B, EIK1003 combined with abiraterone demonstrated favorable tolerability & an objective response rate (ORR) of 20.8% in metastatic prostate cancer.
In Cohort 1C, EIK1003 combined with weekly paclitaxel showed an ORR of 26.4% in platinum-resistant ovarian cancer & HER2-negative breast cancer, with safety consistent with paclitaxel's known profile.
EIK1004, a CNS-penetrant PARP1 inhibitor, demonstrated minimal Grade 3 or higher hematologic toxicities in 68 participants, with an ORR of 12.1% in advanced solid tumors.
EIK1005, a WRN helicase inhibitor, showed a favorable safety profile supporting weekly administration, with preliminary efficacy data indicating stable disease in 75% of monotherapy participants & a partial response in a combination arm with pembrolizumab.
EIK1003 is currently enrolling an additional Cohort 1D combining the drug with paclitaxel & platinum-based chemotherapy, with initial results expected in late 2027.
Additional data for EIK1003, EIK1004, & EIK1005 programs are expected to be reported throughout 2027.